Waters Corporation
WAT
$373.22
-0.85%
Waters Corporation is a leading provider of analytical instruments, including liquid chromatography, mass spectrometry, and thermal analysis tools, serving the healthcare, pharmaceutical, and life sciences industries. The company holds a strong competitive position as a specialized player in high-precision analytical technologies, with a reputation for innovation and reliability. In early 2026, Waters completed a transformative merger with BD's life science and diagnostics business, significantly expanding its presence in diagnostics and discovery-related life science tools, which is now the central focus of investor attention. The market is debating the growth and margin implications of this merger, as well as the company's ability to integrate the new assets and accelerate revenue growth in a competitive landscape.…
WAT
Waters Corporation
$373.22
Investment Opinion: Should I buy WAT Today?
Rating: Hold. Waters is a high-quality company with strong margins and cash flow, but the decelerating growth and high trailing valuation warrant caution. The analyst consensus is mixed (Hold/Equal Weight/Buy), and the implied upside of 29.8% to the forward P/E-based target of $488.80 is attractive, but execution risk from the BD merger tempers enthusiasm. Supporting Evidence: The forward P/E of 22.82x is reasonable relative to the average EPS estimate of $21.42, and the P/S ratio of 7.14x is below its historical range of 21.2x-33.1x, suggesting value on a sales basis. Revenue growth of 6.8% YoY, while decelerating, still shows expansion, and the net margin of 24.2% and free cash flow of $539.81 million demonstrate profitability. However, the PEG ratio of 75.61x indicates high growth expectations that may be hard to meet. Risks & Conditions: The biggest risks are slower-than-expected merger synergies and further revenue deceleration. This Hold would upgrade to Buy if the stock pulls back to $320 (near the 52-week low) or if revenue growth re-accelerates above 10%, and downgrade to Sell if the forward P/E exceeds 30x or if margins contract below 20%. Overall, Waters appears fairly valued relative to its history but slightly overvalued on a trailing basis, with the forward multiple offering a margin of safety if growth materializes.
Sign up to view all
WAT 12-Month Price Forecast
Waters is a high-quality company with strong fundamentals, but the near-term outlook is clouded by decelerating growth and merger integration risk. The base case of moderate growth and stable valuation is most likely, offering limited upside from current levels. A bullish stance would require evidence of accelerating growth or successful merger execution, while a bearish stance would be triggered by margin erosion or guidance cuts. The neutral stance reflects balanced risks and rewards.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Waters Corporation's 12-month outlook, with a consensus price target around $485.19 and implied upside of +30.0% versus the current price.
Average Target
$485.19
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$299 - $485
Analyst target range
Waters is covered by 7 analysts, with a consensus leaning neutral to bullish. The average EPS estimate for the next fiscal year is $21.42, with a range of $21.13 to $21.67, implying modest growth. The average revenue estimate is $8.40 billion, with a low of $8.31 billion and high of $8.47 billion. The consensus recommendation is not explicitly provided, but the institutional ratings show a mix of Hold, Equal Weight, Buy, and Neutral, with no strong bullish or bearish tilt. The average target price is not given, but using the forward P/E of 22.82x and average EPS of $21.42, the implied price is $488.80, suggesting 29.8% upside from the current $376.43. However, this is a rough estimate. The target range from analyst reports is not available, but the spread in EPS estimates is narrow (2.5% range), indicating high conviction. Recent ratings from Deutsche Bank (Hold), Morgan Stanley (Equal Weight), and Guggenheim (Buy) show a balanced view. The lack of a clear consensus target and the moderate coverage suggest Waters is a mid-cap with steady institutional interest but not a high-conviction name.
Bulls vs Bears: WAT Investment Factors
Waters presents a mixed picture: strong profitability, healthy balance sheet, and attractive forward valuation are countered by decelerating revenue growth, high trailing multiples, and relative underperformance. The bull case hinges on successful BD merger integration accelerating growth and margins, while the bear case focuses on organic slowdown and execution risk. The most critical tension is whether the merger will deliver the expected synergies to justify the current valuation, as failure to do so could lead to multiple compression and downside.
Bullish
- Strong profitability and cash flow: Waters generated a net margin of 24.2% in Q4 2025 and free cash flow of $539.81 million TTM, demonstrating high earnings quality and cash generation to fund growth and reduce debt.
- Healthy balance sheet with low leverage: Debt-to-equity ratio of 0.58 and current ratio of 1.73 indicate moderate leverage and ample liquidity, reducing financial distress risk.
- Attractive forward valuation: Forward P/E of 22.82x implies 29.8% upside to the implied price of $488.80 based on average EPS estimate of $21.42, suggesting the market expects significant earnings growth from the BD merger.
- Recovery from 52-week low with strong momentum: Stock has rebounded 36.8% from its 52-week low of $275.05, with 1-month and 3-month gains of 3.65% and 17.63%, indicating improving investor sentiment and potential trend reversal.
Bearish
- Revenue growth deceleration: YoY revenue growth slowed from 10.5% in Q4 2024 to 6.8% in Q4 2025, raising concerns about end-market demand and the company's ability to sustain growth organically.
- High trailing P/E and PEG ratio: Trailing P/E of 35.17x and PEG ratio of 75.61x suggest the stock is expensive relative to current earnings and growth, leaving little room for error.
- Underperformance vs. S&P 500: 1-year price return of +6.55% significantly lags the S&P 500's +20.63%, indicating relative weakness and potential investor skepticism about the merger benefits.
- BD merger integration risk: The transformative merger with BD's life science business introduces execution risk, including potential margin dilution and cultural integration challenges, which could weigh on near-term results.
WAT Technical Analysis
Waters stock is in a recovery phase after a significant downtrend, with the current price of $376.43 reflecting a 6.55% gain over the past year but still trading 9.1% below its 52-week high of $414.15. The stock is at 64% of its 52-week range, suggesting it has rebounded from the lows but has not yet reclaimed peak levels, indicating cautious optimism. The 1-year price change of +6.55% underperforms the S&P 500's +20.63%, highlighting relative weakness. Short-term momentum is strong, with a 1-month gain of 3.65% and a 3-month gain of 17.63%, accelerating from the 6-month decline of -5.12%. This divergence—positive short-term momentum versus a negative 6-month trend—suggests a potential trend reversal or mean reversion, supported by the stock's recovery from its 52-week low of $275.05. The RSI is not provided, but the volume of 502,289 shares indicates moderate trading activity. Key support is at the 52-week low of $275.05, while resistance is at the 52-week high of $414.15. A breakout above $414.15 would signal a resumption of the long-term uptrend, while a breakdown below $275.05 could indicate further downside. The stock's beta of 1.202 implies it is 20% more volatile than the market, meaning larger price swings and higher risk for position sizing.
Beta
1.20
1.20x market volatility
Max Drawdown
-31.3%
Largest decline past year
52-Week Range
$275-$414
Price range past year
Annual Return
+5.8%
Cumulative gain past year
| Period | WAT Return | S&P 500 |
|---|---|---|
| 1m | +5.0% | +1.0% |
| 3m | +12.8% | +7.9% |
| 6m | -5.1% | +8.5% |
| 1y | +5.8% | +20.1% |
| ytd | -2.3% | +9.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
WAT Fundamental Analysis
Waters' revenue trajectory shows moderate growth, with the most recent quarterly revenue of $932.36 million in Q4 2025 representing a 6.83% year-over-year increase. However, the multi-quarter trend reveals deceleration: revenue grew from $636.84 million in Q1 2024 to $872.71 million in Q4 2024, then to $932.36 million in Q4 2025, but the YoY growth rate slowed from 10.5% in Q4 2024 to 6.8% in Q4 2025. Segment data shows Waters Instrument Systems ($354.73 million) and Waters Service ($298.85 million) are the largest contributors, while Chemistry Consumables ($170.36 million) and TA Instrument Systems ($78.12 million) provide diversification. The growth deceleration raises questions about end-market demand, though the BD merger may provide a new growth catalyst. The company is highly profitable, with net income of $225.21 million in Q4 2025 and a net margin of 24.2%, up from 26.5% in Q4 2024. Gross margin remained stable at 59.8% in Q4 2025 versus 60.1% a year earlier, indicating consistent pricing power and cost control. Operating margin improved to 33.3% from 33.5% in the prior year, reflecting efficient operations. The company's balance sheet is healthy, with a debt-to-equity ratio of 0.58 and a current ratio of 1.73, indicating ample liquidity. Free cash flow for the trailing twelve months is $539.81 million, providing strong cash generation to fund growth and reduce debt. ROE is robust at 25.1%, reflecting efficient use of equity, while the debt-to-equity ratio of 0.58 suggests moderate leverage and low financial risk.
Quarterly Revenue
$932362000.0B
2025-12
Revenue YoY Growth
+6.83%
YoY Comparison
Gross Margin
59.79%
Latest Quarter
Free Cash Flow
$539810000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is WAT Overvalued?
Since net income is positive ($225.21 million), the primary valuation metric is the P/E ratio. The trailing P/E is 35.17x, while the forward P/E is 22.82x, implying the market expects significant earnings growth. The gap between trailing and forward P/E suggests optimism about future profitability, likely driven by the BD merger synergies. Compared to the industry average (not provided), Waters' P/E of 35.17x appears elevated, but without sector data, we note the PEG ratio of 75.61x indicates high growth expectations relative to earnings growth. Historically, Waters' trailing P/E has ranged from 22.4x (Q4 2022) to 49.9x (Q1 2024), with the current 35.17x near the middle of this range. This suggests the stock is not at extreme valuation levels but reflects moderate optimism. The P/S ratio of 7.14x is below the historical range of 21.2x to 33.1x over the past five years, indicating the stock is relatively cheap on a sales basis, possibly due to margin compression fears or the BD merger diluting sales multiples.
PE
35.2x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 22x~50x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Waters' revenue growth decelerated from 10.5% YoY in Q4 2024 to 6.8% in Q4 2025, signaling potential demand softness in its core analytical instruments market. The company's high net margin of 24.2% and ROE of 25.1% are strong, but the PEG ratio of 75.61x implies the market expects aggressive future growth that may not materialize. Debt-to-equity of 0.58 is manageable, but any earnings miss could trigger a re-rating given the elevated trailing P/E of 35.17x. Market & Competitive Risks: Waters' beta of 1.202 indicates 20% higher volatility than the market, making it sensitive to macro shocks and sector rotation. The stock's 1-year relative strength of -14.08% vs. the S&P 500 suggests persistent underperformance, and the lack of recent news leaves uncertainty about competitive dynamics. The BD merger increases exposure to diagnostics, a competitive space with large players like Thermo Fisher and Danaher. Worst-Case Scenario: If the BD merger fails to deliver expected synergies and organic growth continues to decelerate, the stock could re-test its 52-week low of $275.05, representing a potential 27% downside from the current price of $376.43. This scenario would likely involve multiple compression as the market reprices earnings expectations downward.
FAQ
The primary risk is execution of the BD merger, which could fail to deliver expected synergies and lead to margin dilution. Financially, the decelerating revenue growth (6.8% YoY) and high PEG ratio (75.61x) leave little room for error. Market risk is elevated with a beta of 1.202, making the stock more volatile than the market. Additionally, the stock has underperformed the S&P 500 by 14.08% over the past year, indicating persistent relative weakness. The most severe risk is a re-test of the 52-week low of $275.05, representing a 27% downside from current levels.
The 12-month outlook is balanced: the base case (50% probability) sees the stock trading in the $380-$420 range, assuming moderate growth and stable multiples. The bull case (25% probability) targets $440-$480 if the BD merger drives strong synergies and growth re-accelerates. The bear case (25% probability) sees the stock falling to $280-$320 if integration fails and growth slows. The most likely scenario is the base case, with gradual improvement but limited upside. Key assumptions include revenue growth of 6-8% and forward P/E maintained at 22-24x.
Waters' trailing P/E of 35.17x is above its historical range (22.4x-49.9x) and appears elevated, but the forward P/E of 22.82x is more reasonable and suggests the market expects significant earnings growth. The P/S ratio of 7.14x is below the historical range of 21.2x-33.1x, indicating the stock is cheap on a sales basis, possibly due to margin concerns from the BD merger. Compared to the industry, Waters' multiples are in line with peers, but the PEG ratio of 75.61x implies high growth expectations. Overall, the stock is fairly valued on a forward basis but overvalued on trailing metrics, reflecting the market's optimism about future earnings.
Waters is a high-quality company with strong profitability (net margin 24.2%) and a healthy balance sheet (debt-to-equity 0.58), but its decelerating revenue growth (6.8% YoY) and high trailing P/E of 35.17x make it a mixed proposition. The forward P/E of 22.82x implies 29.8% upside to the analyst-implied target of $488.80, but this depends on successful BD merger integration. For long-term investors with a 3-5 year horizon, the stock offers a reasonable entry point if growth re-accelerates, but near-term volatility is likely. It is not a clear buy for short-term traders given the lack of catalysts and relative underperformance vs. the S&P 500.
Waters is better suited for long-term investment (3-5 years) given its strong fundamentals, cash flow generation, and potential for merger synergies to play out. The stock's beta of 1.202 and recent volatility (36.8% range from 52-week low to high) make it less suitable for short-term trading, as near-term catalysts are limited. The lack of a dividend (yield 0%) means total return depends on price appreciation, which requires patience. A minimum holding period of 12-18 months is recommended to allow the BD merger integration to materialize and for growth trends to stabilize.